Research programme: neurodegenerative disease therapies - Cambria Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disease therapies - Cambria Pharmaceuticals

Alternative Names: CMB-03350; CMB-44282; CMB-50213; CMB-50381; CMB-53042

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambria Biosciences LLC
  • Developer Cambria Pharmaceuticals; Northwestern University
  • Class Small molecules
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Cerebral ischaemia
  • Discontinued Brain injuries; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cerebral-ischaemia in USA
  • 07 Nov 2007 Pharmacodynamics data from an in vitro study in Amyotrophic lateral sclerosis presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top